T. Rowe Price Investment Management, Inc.
Position in FATE — Fate Therapeutics Inc
CIK 1897612
BALTIMORE, MD
Position in FATE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$2,916,864
+$2,417,360 QoQ
Shares Held
1,080,320
+929.5% QoQ
Ownership
0.902%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#13
of 156 holders
Holding Since
Sep 2022
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in FATE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026T. Rowe Price Investment Management, Inc. holds $12,305,680,119 across 52 Biotechnology names. FATE ranks #49 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
6,754,846 | $1,801,652,525 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
5,642,173 | $1,698,463,338 | |
| 3 | CYTK |
Cytokinetics Inc
|
18,718,498 | $1,594,628,844 | |
| 4 | KYMR |
Kymera Therapeutics, Inc.
|
6,257,261 | $717,520,118 | |
| 5 | PCVX |
Vaxcyte, Inc.
|
12,207,450 | $709,619,068 | |
| 6 | DYN |
Dyne Therapeutics, Inc.
|
30,912,287 | $686,561,894 | |
| 7 | CGON |
CG Oncology, Inc.
|
6,616,899 | $470,130,673 | |
| 8 | IMNM |
Immunome Inc.
|
19,676,883 | $416,953,150 |
All Filings in FATE
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,916,864 | 1,080,320 | Shares | Sole | 2026-08-14 | |
| 2023-06-30 | $499,504 | 104,938 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $570,456 | 100,080 | Shares | Sole | 2023-05-15 | |
| 2022-12-31 | $4,377,738 | 433,869 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $9,101,687 | 406,144 | Shares | Sole | 2022-11-14 | |
| No filing history on record for this holder in this stock. | ||||||